RxDoctor Payments Data

Sudha Kumar

Family · Elizabethton, TNNPI 1275169187

Payments from drug & device makers

$641in general payments, 2019–2025

Across 24 payments — averaging $26.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$278
  • AbbVie$116
  • Lilly USA, LLC$85
  • Boehringer Ingelheim$60
  • Novo Nordisk$38
  • Xeris Pharmaceuticals, Inc.$20
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$641100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$641 in reported general payments places this provider in the 55th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$23,794
Medicare patients
113
Services billed
694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin21$22,944
MounjaroTirzepatide18$18,647
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,077
Omeprazole37$926
Losartan Potassium37$494
Atorvastatin Calcium58$450
Albuterol Sulfate HfaAlbuterol Sulfate21$375
Fluticasone Propionate14$370
Lisinopril53$304
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$263
Gabapentin18$223
Amitriptyline Hcl11$192
Amlodipine Besylate29$192
Doxycycline Hyclate19$188
Pramipexole DihydrochloridePramipexole Di-Hcl16$188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$60$22,94421 claims
Lilly USA, LLCMounjaro$85$18,64718 claims
GSKTrelegy Ellipta$16$16,07719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 6,706 family providers in Tennessee.

Other family in Elizabethton

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →